Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04708470CT.gov A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Vaginal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Entinostat (this asset) | National Cancer Institute (NCI) | P1/2 | CC · 47 |
| Fludarabine | Christian Hinrichs | P2 | BB |
| Cyclophosphamide | Christian Hinrichs | P2 | BB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Alliance for Clinical Trials in Oncology | P3 | B |
| Durvalumab | M.D. Anderson Cancer Center | P2 | B |
| e7 tcr-t cells | Christian Hinrichs | P2 | B |
| Fondaparinux | Masonic Cancer Center, University of Minnesota | P2 | B |
| Young Til | National Cancer Institute (NCI) | P2 | B |
| Belzutifan | Dana-Farber Cancer Institute | P2 | CCC |
+19 more in the Vaginal Cancer cohort
Other indications for Entinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P2 | B · 63 |
| Myelodysplastic Syndrome | — | P2 | B · 62 |
| Breast Carcinoma | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FludarabineChristian HinrichsBB
- CyclophosphamideChristian HinrichsBB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-Alliance for Clinical Trials in OncologyB
- DurvalumabM.D. Anderson Cancer CenterB
- e7 tcr-t cellsChristian HinrichsB
Citation
Floatz Terminal. Entinostat in Vaginal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/entinostat-vaginal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →